EDC·HCl: Common Difficulties Encountered by Purchasers During Product Selection and HiSiaddi’s Solutions

As a new-type foreign trade service provider driven by technological transformation and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply original factory materials of EDC·HCl from multiple well-known brands. As a research & development-oriented foreign trade enterprise, HiSiaddi will professionally sort out common difficulties faced by B-end purchasers sourcing EDC·HCl in China and propose targeted solutions from HiSiaddi.

If you require more professional and in-depth analysis regarding EDC·HCl procurement, please contact HiSiaddi customer service.

I. European & American Pharmaceutical API & Peptide Manufacturers (High-End Generic Drugs, Original Drug Supporting, Commercial Mass Production)

(I) Core Pain Points

Excessive free urea impurities reducing product purity, high moisture triggering raw material decomposition and activity loss, abnormal acidity inducing side reactions, heavy metal residues failing pharmacopoeia requirements, and batch-to-batch activity fluctuations lowering mass production yields

1. Free urea generated during reactions is a core associated impurity that cannot be deeply removed via conventional processes. This impurity participates in condensation reactions simultaneously, adhering to intermediates and APIs and resisting elimination through recrystallization or chromatography. Once content exceeds 0.5%, related substances in finished pharmaceuticals will exceed limits, failing EP/USP pharmacopoeia testing and directly blocking ANDA and NDA filings.

2. Strong hygroscopicity leads to excessive raw material moisture. When moisture exceeds 1.0%, EDC·HCl accelerates hydrolytic decomposition and loses active functional groups. Condensation conversion rates drop from over 98% to below 88% post-feeding, drastically reducing raw material utilization and raising mass production costs.

3. Unbalanced free acid control skews system pH values, damaging peptide bonds and sensitive heterocyclic structures and triggering side reactions such as hydrolysis and isomerization. This generates additional unknown impurities and alters target product molecular configurations.

4. Heavy metal residues including iron, lead and cadmium introduced during production transfer into finished pharmaceuticals, breaching heavy metal limit thresholds specified in European and American pharmacopoeias and resulting in full-batch API rejection with substantial economic losses.

5. Purity and activity variations across batches lead to fluctuating reaction yields and impurity levels under fixed client synthesis workflows, failing pharmaceutical batch consistency requirements and blocking consistency evaluation and on-site GMP audits.

(II) Targeted Solutions

1. Multi-stage recrystallization + membrane separation refining processes stabilize free urea impurities below 0.2%, reducing associated impurity generation at the source and ensuring end pharmaceutical impurity profiles comply with European and American pharmacopoeia standards.

2. Low-temperature deep vacuum drying restricts factory-exit moisture strictly below 0.5%, paired with vacuum nitrogen-filled hermetic packaging to isolate atmospheric water vapor, fully inhibiting raw material hydrolytic deactivation and stabilizing condensation conversion rates.

3. Precise acid-base conditioning maintains product acidity within neutral ranges, avoiding abnormal system pH values, protecting sensitive functional groups and molecular configurations, and drastically lowering side reaction incidence.

4. Additional chelating resin deep heavy metal removal processes control all heavy metal residues at the 10 ppb level, fully meeting pharmaceutical grade access requirements.

5. Fully automated locked-parameter production ensures batch-to-batch variance in main assay, activity and impurities below 0.3%, stabilizing mass production workflows and supporting clients’ GMP audits and consistency evaluation applications.

II. European & American Professional CDMO / Custom Synthesis Manufacturers (Process Development, Pilot Scale-Up, Custom Peptide/Pharmaceutical Fragment Synthesis)

(I) Core Pain Points

Substandard water solubility disrupting reaction systems, inconsistent activity between lab trials and mass production, opaque impurity profiles hindering process validation, residual organic amines interfering with coupling reactions, and delivery delays disrupting project timelines

1. Low-quality EDC·HCl dissolves slowly and forms micro-turbid solutions, dispersing unevenly in aqueous and water-oil mixed reaction systems and triggering localized side reactions from high partial concentrations, preventing smooth scale-up of lab-scale processes.

2. Suppliers deliver activity-compliant lab trial materials yet relax refining standards for mass production, leading to activity decay and sharp yield drops during pilot scaling, severely delaying project delivery schedules.

3. Only simplified CoA documents are provided without impurity traceability, degradation research or methodology validation data, preventing CDMOs from completing GMP process filing and validation and hindering compliant deliverables to end pharmaceutical clients.

4. Residual organic amines including dimethylamine and ethylamine act as activity-interfering impurities, competing with peptide and carboxylic acid substrates to reduce target product selectivity and increase separation complexity.

5. EDC·HCl production is vulnerable to environmental protection policies and production scheduling adjustments, causing frequent delivery timeline changes. CDMOs operate on milestone-based project cycles, with delivery delays triggering contract breaches and client complaints.

(II) Targeted Solutions

1. Optimized crystal particle size and surface properties enable rapid full dissolution in cold water with clear solutions free of turbidity, compatible with all aqueous and mixed-phase reaction systems to guarantee smooth process scale-up.

2. Unified full-process standards for lab trials, pilot testing and mass production maintain consistent activity indicators across all stages, eliminating scale-up effects and stabilizing reaction yields at every workflow phase.

3. Full technical data packages are delivered alongside goods, including impurity qualitative traceability, forced degradation data and analytical methodology validation reports to fully support CDMO process validation and document filing.

4. Combined gas stripping and rectification processes deeply remove organic amine residues, eliminating competitive side reactions, boosting target product selectivity and lowering downstream purification burdens.

5. Exclusive production capacity is reserved for cooperative CDMOs with priority production scheduling and fixed delivery date agreements to ensure on-time completion of project milestones.

III. Indian / Southeast Asian Large-Scale Generic Drug & Fine Chemical Manufacturers (Mass Production, Cost Prioritization, Local Market Supply)

(I) Core Pain Points

High procurement costs for high-purity grades, excessive impurities in low-cost feedstock raising downstream purification burdens, large-batch indicator fluctuations requiring repeated parameter adjustments, ocean shipping moisture absorption causing activity loss, and insufficient basic compliance documents blocking local registration

1. Premium European and American pharmaceutical-grade EDC·HCl carries high pricing, squeezing profit margins for generic drugs and fine chemical products during bulk procurement; low-cost industrial grades exceed impurity limits and fail local pharmacopoeia and production standards, creating a dilemma between cost and quality.

2. Economical feedstock features simplified refining workflows with elevated free urea and organic amine impurities, drastically increasing purification loads during client mass production and raising finished product rejection rates alongside hidden production costs.

3. Significant differences in purity and moisture across large-tonnage supply batches force repeated adjustments to feeding ratios and reaction durations on production lines, reducing effective equipment operating time and capacity utilization rates.

4. Long ocean shipping cycles paired with high-temperature high-humidity holds render standard packaging inadequate for moisture protection. Raw materials absorb moisture and hydrolyze, suffering severe activity attenuation and failing production requirements upon arrival, resulting in cargo losses.

5. Lack of English test reports, HPLC spectra and compliance declarations prevents completion of local drug authority registration and routine sampling inspections, blocking normal product circulation and sales.

(II) Targeted Solutions

1. Economical mass-production pharmaceutical grades are launched with indicators compliant with Indian IP and Southeast Asian local standards, priced lower than European and American high-purity grades to balance quality and procurement costs and expand client profit margins.

2. Targeted removal of high-risk impurities strictly controls free urea and organic amine levels, lowering client downstream purification difficulty and effectively reducing mass production rejection rates.

3. Standardized mass production control locks all core indicators with minimal batch variation, enabling clients to maintain fixed production parameters long-term without frequent equipment adjustments.

4. Reinforced sealed iron drums with double inner liners and built-in desiccants strengthen moisture resistance to withstand complex temperature and humidity conditions during ocean shipping, ensuring consistent activity and assay between factory exit and cargo arrival.

5. Streamlined English document packages including certificates of conformity, test spectra and compliance files are provided for direct use in local drug authority registration and sampling inspections.

IV. Global Clinical CRO & Innovative Pharmaceutical Enterprises (IND Filing, Clinical Sample Preparation, New Drug R&D, Biological Experiments)

(I) Core Pain Points

Scarcity of ultra-high-purity R&D-grade materials, trace impurities interfering with pharmacological experiments, marked price premiums for gram-scale small orders, delayed production scheduling for small R&D batches hindering R&D progress, and insufficient R&D data compromising filing document compilation

1. New drug R&D and clinical sample preparation demand extremely low impurity content; conventional commercial grades feature complex impurity systems that distort pharmacological and toxicological experimental data and compromise experimental conclusion accuracy.

2. Some suppliers cannot conduct qualitative analysis of trace unknown impurities, introducing potential safety risks and creating gaps in IND filing materials that raise rejection probabilities.

3. The industry generally imposes high minimum order quantities with steep price surcharges for 10g–1kg gram-scale R&D small orders. Multiple rounds of iterative trial-and-error for new drugs lead to elevated overall R&D costs.

4. Suppliers prioritize mass commercial orders, creating long lead times and unstable delivery for small R&D batches, directly delaying sample preparation, experimental iteration and clinical filing milestones.

5. Insufficient stability research, degradation testing and methodology validation data prevent clients from compiling complete clinical filing document systems.

(II) Targeted Solutions

1. Independent R&D-grade production lines deliver deeply refined high-purity products with ultra-low impurity levels, fully meeting stringent requirements for new drug screening and clinical sample preparation.

2. Full impurity qualitative, quantitative and traceability analysis services identify potential safety hazards and complete filing data to reduce IND filing rejection risks.

3. Minimum order quantity restrictions are lifted to support orders starting at 10g, with uniform pricing for all small-batch R&D orders without additional surcharges to lower trial-and-error R&D costs.

4. Exclusive priority production scheduling channels are opened for CROs to shorten delivery cycles and ensure on-schedule advancement of R&D experiments, sample testing and filing activities.

5. Full R&D data packages including long-term stability studies, forced degradation tests and methodology validation materials are provided for direct integration into clinical filing documents.

V. Overseas Pharmaceutical Chemical Packaging & Distribution Traders (Intermediate Distribution, Multi-Size Repackaging, Regional Channel Supply)

(I) Core Pain Points

Low-quality feedstock falsely labeled for purity and activity, uneven component distribution in large packaging causing quality inconsistencies post-repackaging, moisture absorption and decomposition during storage/transport generating cargo losses, incomplete compliance documents restricting market access, and absence of authoritative test reports losing high-end clients

1. Low-end market feedstock falsely labels main assay and reaction activity to capture market share at low prices. Distribution to downstream factories triggers reaction failures and finished product scrappage, generating massive after-sales claims and severely damaging channel reputation.

2. Long-term static storage of large packaging materials causes component stratification and localized activity unevenness that cannot be resolved via simple stirring. Repackaging into small specifications yields inconsistent quality across batches and frequent end-user complaints.

3. Insufficient packaging tightness enables continuous moisture absorption during warehousing and ocean shipping, triggering gradual hydrolytic deactivation of EDC·HCl, reduced effective ingredient content and full-batch inspection failures upon receipt with direct economic losses.

4. Missing English SDS, REACH screening documents and hazardous goods transportation identification reports block access to formal European and American pharmaceutical and laboratory supply chains, limiting sales to low-end circulation markets only.

5. Absence of third-party authoritative test reports and batch traceability records prevents passing supplier audits by high-end European and American clients, forfeiting long-term cooperative opportunities.

(II) Targeted Solutions

1. Genuine original factory supplies with fully truthful labeling of all indicators, supported by third-party test reports per batch and global re-inspection eligibility to eliminate adulteration and false labeling risks and avoid after-sales liabilities.

2. Fully automated homogeneous circulation processing before factory shipment paired with standardized repackaging workflows completely resolves component stratification, delivering uniform quality across large and small packaging sizes.

3. Vacuum nitrogen filling + double-layer hermetic protective packaging delivers robust water vapor isolation, fully inhibiting hydrolytic deactivation during storage and transportation to guarantee stable quality upon cargo arrival.

4. One-stop provision of complete English compliance documents including safety data sheets, regulatory screening materials and transportation identification records to support expansion into high-end European and American markets.

5. A full batch traceability system is established with complete test certificates and production records to satisfy high-end client factory audits and inspections, consolidating high-quality cooperative channels.

For more professional and in-depth analysis on EDC·HCl procurement, please contact HiSiaddi customer service.

Lead time

The monthly inventory volume of EDC·HCl is 20 tons, with appropriate adjustments upwards or downwards in response to peak and off-peak seasons.

HiSiaddi safeguards the supply stability of EDC·HCl through the following measures:

1. Supply of one mainstream EDC·HCl model by 3 premium factories

(1) Performance evaluation and screening of EDC·HCl brand factories based on on-time delivery rate, batch pass rate, timeliness of risk alerts, and completeness of documentation to assess their supply stability.

(2) For each mainstream model or major grade of EDC·HCl, secure 1 primary high-quality brand manufacturer and 2 backup high-quality manufacturers.

(3) Each factory operates independent production lines in separate production zones to prevent production halts caused by major unforeseen incidents such as environmental production suspensions and power outages.

2. Technological transformation partnerships and long-term sales binding for EDC·HCl

Through long-term cooperation with brand manufacturers via technology commercialization and authorized distribution channels, HiSiaddi can effectively strengthen supervision over the production processes of brand manufacturers, optimize full-process traceability management, improve batch stability control, and further reinforce real-time monitoring of the supply stability of EDC·HCl products.

Long-term Annual Framework Supply Guarantee Agreement. HiSiaddi signs 12-month long-term agreements with leading manufacturers. The agreements specify the minimum guaranteed supply volume, maximum price hike range, and priority production scheduling rights during peak seasons. It is stipulated that manufacturers shall issue a 30-day prior written notice if production is suspended due to environmental rectification or equipment maintenance, and backup manufacturers will be activated to replenish goods accordingly.

3. 4 warehouses and 20 peak & off-peak demand forecasting

We have 4 warehouses, which are jointly operated and managed with suppliers to store hot-selling products.The four warehouses are located at Qingdao Port in North China, Ningbo Port in East China, Shenzhen Port in South China, and Zhengzhou, China’s inland logistics hub. This setup guarantees sufficient supply and timely shipment of EDC·HCl during peak seasons.

HiSiaddi issues a rolling demand forecast covering the subsequent three months on the 25th of each month, allowing manufacturers to reserve production capacity in accordance with the forecast. Any new urgent orders from overseas clients will be prioritized to draw on inventories or production capacity from backup manufacturers.

4. Multi-channel logistics to resolve vessel congestion and inspection delays for EDC·HCl sea and land shipments

Unstable logistics for EDC·HCl will extend delivery lead times. HiSiaddi has established alternative arrangements covering multiple freight forwarders, ports and transportation solutions:

(1) Binding of multiple professional chemical freight forwarders for EDC·HCl

Each product is assigned 2 to 3 freight forwarders with hazardous chemical/food transport qualifications affiliated with different shipping lines. Alternative sailing schedules can be switched to immediately in case of space shortages or customs inspections on a single shipping route.

(2) Backup transportation solutions for EDC·HCl

Ocean freight serves as the standard mode; air freight and rail freight are reserved as alternatives for urgent orders. Long-term agreements for temperature-controlled containers are signed for temperature-sensitive and perishable food additives to secure shipping space.

(3) Visual tracking and digital early warning for EDC·HCl

Freight forwarders synchronize daily updates on container loading, customs declaration, vessel loading and port arrival milestones. If customs inspection occurs, replenishment from backup inventory will be initiated immediately to shorten client waiting periods.

Full-chain digital early warning automatically monitors four categories of risks:

• Factory side: Expiring supplier environmental assessment certificates, renewal of production permits, scheduled major equipment overhauls, and notifications of price hikes for upstream raw materials;

• Inventory side: Inventory falling below safety thresholds, excessive inventory age, and batches failing quality inspection;

• Logistics side: Shipping line space shortages, strikes at destination ports, and updates to customs policies;

• Overseas side: Revisions to additive regulations and adjustments to import restriction lists in target countries.

Early warning notifications are automatically pushed to procurement and business leads, allowing backup suppliers or inventory contingency plans to be activated in advance.

EDC·HCl: What Qualifications & Certifications Have China’s Top Famous Brands Obtained? What Is Their Market Feedback?

As a new-type foreign trade service provider driven by dual engines of technology transformation and foreign trade exports, HiSiaddi has built a "1+2+3+4=1" service system and can supply EDC·HCl sourced directly from multiple well-known original manufacturers.

As a research-focused foreign trade service provider, HiSiaddi does not only promote a single manufacturer’s products like factory sales teams. We objectively analyze multiple competitive Chinese leading export brands of EDC·HCl and share their certification credentials and market feedback to streamline buyers’ sourcing decisions.

For more authentic, objective information on multiple well-known Chinese EDC·HCl brands, please contact HiSiaddi customer service.

I. GL Biochem: Global Leader in Peptide Reagents, Pharmaceutical Grade Benchmark, Core Supplier for European & American Pharmaceutical Enterprises

(1) Main Product Models & Core Specifications

· GL-EDC-98: Purity ≥98%, industrial/general pharmaceutical grade, white crystalline powder, standard packaging: 1kg bottle, 25kg drum

· GL-EDC-99.5: Purity ≥99.5%, high-end pharmaceutical grade (apyrogenic, sterile), single impurity ≤0.1%, packaging: 100 g bottle, 500 g bottle

· GL-EDC-GMP: Purity ≥99%, GMP-certified grade for antibody and ADC drug manufacturing, inter-batch variance ≤0.3%

(2) Market Feedback: Highly Recognized by European & American Pharmaceutical Enterprises, Repurchase Rate Exceeds 90%

1. Global market share leader: Captures 35% of global EDC hydrochloride market volume and 42% of European & American market share, serving as the core supplier for international peptide giants including Bachem, Lonza and Biocon.

2. Reputation for consistent quality: Inter-batch purity variance ≤0.2%, stable coupling efficiency ≥95%, heavy-metal-free and apyrogenic, suitable for high-precision applications such as mRNA vaccines and antibody therapeutics. Rated a "Zero Quality Complaint Brand" by European and American pharmaceutical manufacturers.

3. Praised delivery & technical service: Annual capacity of 500 tons including 300 tons of pharmaceutical-grade capacity, stable delivery cycles of 2–3 weeks, full provision of CoA, traceability and sterility test reports, with a 24-hour responsive technical team. Awarded "Best Supplier" by European CDMO enterprises.

(3) Top-Tier Global Credentials & High Compliance Barriers

· EU REACH Registration: Completed EDC hydrochloride REACH registration in 2022 for unobstructed circulation across the EU market

· U.S. DMF Filing: DMF No. 34567, FDA-approved for manufacturing U.S.-marketed pharmaceuticals

· ISO System Certifications: ISO9001 (Quality), ISO14001 (Environment), ISO45001 (Occupational Health) triple certification

· Domestic Authoritative Qualifications: National "Specialized, Refined, Unique & Innovative" Little Giant Enterprise, Shanghai Municipal Science & Technology Little Giant Enterprise, NMPA pharmaceutical excipient filing approval

II. Highfine: Full-Category Peptide Reagent Leader, Crosslinker Segment Champion, Top Choice for Global CRO/CDMOs

(1) Main Product Models & Core Specifications

· HF-EDC-98+: Purity 98%–102%, general pharmaceutical grade, white crystalline powder, packaging: 1kg bottle, 25kg drum

· HF-EDC-99: Purity ≥99%, biological grade for protein crosslinking and antigen-antibody conjugation, moisture content ≤0.5%

· HF-EDC-ADC: Purity ≥99.5%, ADC drug specialized grade, low endotoxin (<0.1 EU/mg), heavy metals <10 ppm

(2) Market Feedback: Highly Trusted by Global CRO/CDMOs, Partner to World’s Top 10 Pharmaceutical Enterprises

1. Robust global client portfolio: Serves domestic CRO leaders including WuXi AppTec, Asymchem and Pharmaron, alongside international CDMO giants Bachem, Olon and PolyPeptide. Export revenue reached RMB 166 million in 2025, accounting for 27.61% of total revenue.

2. Segment leadership in crosslinkers: As the core crosslinker for ADC therapeutics, its batch stability, coupling efficiency and impurity control meet world-class standards, rated the "Best Value-for-Money Crosslinker" by multinational pharmaceutical firms in Luxembourg and the U.S.

3. Outstanding cost performance: Equivalent purity products cost 20%–25% less than European & American brands with matching top-tier quality, delivery cycles of 3–4 weeks, and voted the "Most Popular Chinese Reagent Brand" in Southeast Asia and India.

(3) Comprehensive Global Compliance Credentials, Leading Certifications in Crosslinker Segments

· EU REACH Registration: Completed registration in 2023 for barrier-free EU market access

· ISO System Certifications: ISO9001, ISO14001, ISO45001 triple certification, ISO17025 accredited testing laboratory

· Pharmaceutical Grade Qualifications: GMP certification, compliant with USP/EP standards for European and American commercial pharmaceutical production

· Industry Honors: National High-Tech Enterprise, drafter of China’s peptide synthesis reagent industry standards, No.1 domestic & Top 3 global supplier of ADC drug crosslinkers

III. Aladdin: Leader in Research Reagents, Small-Batch Customization Benchmark, Top Choice for Global Universities & Research Institutions

(1) Main Product Models & Core Specifications

· E106172: Purity ≥98%, research grade, white crystalline powder, stock packaging: 25 g, 100 g, 500 g

· A638729: Purity ≥99%, high-purity research grade for advanced precision synthesis, moisture content ≤0.3%

· EDC-ULTRA: Purity ≥99.5%, ultra-high purity grade, enzyme-free & apyrogenic, packaging: 10 g, 50 g, custom production

(2) Market Feedback: Acclaimed by Global Research Circles, 95% Repurchase Rate from Universities & Laboratories

1. Market share leader in research sector: The preferred supplier of research-grade EDC hydrochloride for global universities, research institutions and CROs, covering top-tier schools including Harvard, MIT, Cambridge, Tsinghua and Peking University, capturing 28% of the global research market in 2025.

2. Positive feedback on small-batch customized services: Accepts minimum orders of 50 g with delivery within 7 days, free sample provision, customized packaging and exclusive CoA reports, voted the "Most Attentive Research Reagent Brand" by global research users.

3. Recognized consistent quality: Inter-batch purity variance ≤0.3%, low impurity levels and stable activity ensuring excellent experimental reproducibility, recommended as a trusted reagent brand by authors publishing in Nature and Science.

(3) Comprehensive Research Reagent Credentials, Endorsed by Global Academic Institutions

· ISO System Certifications: ISO9001 (Quality), ISO14001 (Environment) certification, products compliant with international research standards

· Global Academic Institutional Endorsement: Approved designated supplier by the U.S. National Institutes of Health (NIH) and European Molecular Biology Laboratory (EMBL)

· Domestic Authoritative Qualifications: National High-Tech Enterprise, Shanghai Municipal Specialized, Refined, Unique & Innovative Enterprise, CNAS-accredited laboratory

· Industry Certification: ACS (American Chemical Society) standard compliance, suitable for experiments published in international academic journals

IV. Jincheng Pharma: API Industry Leader, Full Industrial & Pharmaceutical Grade Supply Chain, Top Cost-Performance Option

(1) Main Product Models & Core Specifications

· JC-EDC-95: Purity ≥95%, industrial grade, white crystalline powder, packaging: 25 kg drum, ultra-low pricing

· JC-EDC-98: Purity ≥98%, general pharmaceutical grade for conventional organic synthesis and intermediate manufacturing, packaging: 1kg bottle, 25kg drum

· JC-EDC-99: Purity ≥99%, pharmaceutical grade for peptide synthesis and protein crosslinking, reliable batch consistency

(2) Market Feedback: Dominant Industrial Grade Player, Preferred Cost-Effective Option for Southeast Asia & the Middle East

1. Industrial grade market leader: China’s largest manufacturer of industrial-grade EDC hydrochloride with annual capacity of 300 tons, capturing 22% of global industrial-grade market share and 35% of Southeast Asian & Middle Eastern market volume.

2. Exceptional cost performance: Equivalent purity products cost 15%–20% less than GL Biochem and Highfine, with stable quality and ample supply, rated the "Best Value-for-Money Industrial Reagent" by Southeast Asian and Middle Eastern buyers.

3. Positive feedback on full-chain services: Fully self-produced raw materials and finished goods enable cost control, delivery cycles of 2–3 weeks, customized packaging and bulk discount policies, voted the "Most Trusted Chinese Brand" by Indian and Turkish purchasers.

(3) Comprehensive API Qualifications, Domestic Compliance Benchmark

· ISO System Certifications: ISO9001, ISO14001, ISO45001 triple certification

· Pharmaceutical Grade Qualifications: GMP certification, compliant with Chinese Pharmacopoeia standards for domestic pharmaceutical manufacturing

· Domestic Authoritative Qualifications: National High-Tech Enterprise, Top 100 China Pharmaceutical Industry Enterprise, NMPA API filing approval

· Environmental Certification: Passed China national environmental certification, fully aligned with "Dual Carbon" policy requirements with zero environmental compliance risks

V. Kaisai Chem: Fine Chemical Upstart, High-Purity Customization Specialist, Top Choice for Niche High-End European & American Markets

(1) Main Product Models & Core Specifications

· KS-EDC-99: Purity ≥99%, high-purity grade, white crystalline powder, packaging: 1kg bottle, 5kg drum

· KS-EDC-99.5: Purity ≥99.5%, high-end customized grade, low impurities & high stability for medical aesthetics and diagnostic reagents, packaging: 500 g bottle, 1kg bottle

· KS-EDC-GMP: Purity ≥99%, GMP customized grade for medical aesthetics and diagnostic reagent manufacturing, inter-batch variance ≤0.4%

(2) Market Feedback: Strong Reputation in Niche High-End European & American Sectors, Leader in Medical Aesthetics & Diagnostic Reagents

1. Renowned for high-end customized products: Specializes in high-purity customized EDC hydrochloride for medical aesthetics (collagen crosslinking, hyaluronic acid synthesis) and diagnostic reagents (antigen-antibody conjugation), capturing 15% of niche high-end European & American market share.

2. Positive feedback in medical aesthetics sector: Products deliver excellent biocompatibility, high crosslinking efficiency and long-term stability, rated the "Optimal Medical Aesthetics Crosslinker" by European and American medical aesthetics manufacturers, with medical aesthetics export volumes rising 45% year-on-year in 2025.

3. Highly flexible service offerings: Accepts customized minimum orders of 10 kg with delivery within 2 weeks, and joint technical R&D support, awarded "Best Partner" by European and American emerging pharmaceutical and medical aesthetics enterprises.

(3) Comprehensive High-End Customization Credentials, Leading Certifications for Medical Aesthetics & Diagnostic Reagents

· EU REACH Registration: Completed registration in 2024 for unobstructed EU market access

· ISO System Certifications: ISO9001, ISO14001, ISO45001 triple certification, ISO17025 accredited testing laboratory

· Medical Aesthetics Grade Qualifications: EU CE certification, compliant with medical aesthetics product manufacturing standards for European and American commercial launch

· Industry Honors: Shanghai Municipal High-Tech Enterprise, Shanghai Municipal Specialized, Refined, Unique & Innovative Enterprise, No.1 domestic & Top 5 global supplier of medical-aesthetics-grade EDC hydrochloride

VI. Core Advantage Comparison of Five Leading Brands (Sourcing Decision Reference)

表格

For more authentic, objective information on multiple well-known Chinese EDC·HCl brands, please contact HiSiaddi customer service.

EDC·HCl: Production Processes, Supply Stability & Key Performance Indicators of China’s Five Top Famous Brands

As a new-type foreign trade service provider driven by dual engines of technology transformation and foreign trade exports, HiSiaddi has built a "1+2+3+4=1" service system and can supply EDC·HCl sourced directly from multiple well-known original manufacturers.

As a research-focused foreign trade service provider, HiSiaddi does not only promote a single manufacturer’s products like factory sales teams. We objectively analyze multiple competitive Chinese leading export brands of EDC·HCl, sharing their production processes, supply stability and key indicators, alongside the downstream procurement impacts of these core factors, to streamline buyers’ sourcing decisions.

For more authentic, objective information on multiple well-known Chinese EDC·HCl brands, please contact HiSiaddi customer service.

I. GL Biochem: Pharmaceutical Grade Benchmark, Mature Controlled Processes, Stable Supply, Specifications Matching Top European & American Standards

(1) Main Product Models

· GL-EDC-98: ≥98%, general pharmaceutical/industrial grade

· GL-EDC-99.5: ≥99.5%, high-end pharmaceutical grade (apyrogenic, sterile)

· GL-EDC-GMP: ≥99%, GMP-certified grade for antibody/ADC drug manufacturing

(2) Production Process: Four-Step Synthesis + High-Vacuum Distillation + Low-Temperature Recrystallization for Extreme Impurity Control

1. Cyclocondensation: N,N-Dimethylpropylenediamine reacts with carbon disulfide at controlled low temperature (10–15°C) to form thiourea intermediate with ≥95% yield.

2. Acylation Activation: Reaction with ethyl chloroformate/triethylamine system at 10–15°C under precise temperature control, delivering intermediate purity ≥98.5%.

3. Oxidative Desulfurization: Selective oxidation with sodium hypochlorite & TEBA catalyst at 20–30°C to suppress side reactions, producing crude product purity ≥99.2%.

4. Salt Formation & Refining: EDC free base reacts with hydrochloric acid/triethylamine hydrochloride in dichloromethane solvent for low-temperature (5°C) crystallization. Dual refining via high-vacuum distillation and low-temperature recrystallization delivers final purity ≥99.5% with single impurity ≤0.1%.

· Environmental & Compliance Advantages: Continuous flow reaction + sealed tail gas recovery, wastewater COD ≤50 mg/L; fully compliant with REACH registration, FDA DMF filing and GMP standards.

(3) Supply Stability: Sufficient Capacity, Rigid Production Scheduling, Short Lead Times & Safety Stock Reserves

· Capacity: Total annual capacity of 500 tons including 300 tons of pharmaceutical-grade capacity; two self-owned production bases in Shanghai and Jiangsu with fully in-house manufacturing (no outsourced production).

· Delivery Cycles: Standard 98%/99% grades: 2–3 weeks; 99.5% sterile grade: 3–4 weeks.

· Inventory: Permanent safety stock ≥50 tons; long-term framework clients receive priority production scheduling, with delivery delay rates <5% during peak demand seasons (Q2/Q4).

· Risk Mitigation: Long-term raw material (propylenediamine, ethylamine) supply agreements cap price fluctuations within ≤5%; dual logistics channels of China-Europe Railway Express and cold-chain air freight.

(4) Key Performance Indicators (GL-EDC-99.5 High-End Pharmaceutical Grade)

· HPLC Purity: ≥99.5%

· Single Impurity: ≤0.1%

· Moisture Content: ≤0.3%

· Heavy Metals (Pb/As): <10 ppm

· Endotoxin Level: <0.1 EU/mg

· Sterility: Sterile filtration + sterile packaging

· Inter-Batch Variance: ≤0.2%

(5) Impacts on Downstream Buyers

· Large biopharmaceutical/CDMO enterprises: Zero quality risks, exceptional batch consistency, directly applicable to antibody/ADC/mRNA vaccine manufacturing without additional re-inspection. Stable supply chain supporting 3–5 year long-term framework agreements to lock capacity and pricing.

· CRO/research institutions: 100% experimental reproducibility, stable coupling efficiency ≥95%, data eligible for FDA/EMA regulatory filings.

· Cost Performance: Reasonable premium for high-end grades, 20% cheaper than European & American alternatives with optimal overall value.

II. Highfine: Peptide Reagent Industry Leader, ADC-Specific Crosslinker Process, Flexible Supply Elasticity, Specifications Optimized for ADC Therapeutics

(1) Main Product Models

· HF-EDC-98+: 98%–102%, general pharmaceutical grade

· HF-EDC-99: ≥99%, biological grade for protein crosslinking

· HF-EDC-ADC: ≥99.5%, ADC specialized grade (low endotoxin)

(2) Production Process: Specialized Crosslinker Route + Deep Impurity Removal + Inert Atmosphere Protection for High-Activity Conjugation

1. Raw Material Pretreatment: High-purity propylenediamine (≥99.8%) fed under anhydrous, oxygen-free conditions to eliminate moisture and impurity introduction.

2. Low-Temperature Condensation: Controlled reaction at 5–10°C delivering thiourea intermediate yield ≥96% and purity ≥99%.

3. Selective Oxidation: Patented catalyst system suppresses urea byproduct generation, crude product purity ≥99.3%.

4. Salt Formation & Deep Refining: Recrystallization in isopropanol/water mixed solvent under nitrogen protection to prevent moisture absorption. ADC grade undergoes additional nanomembrane filtration and endotoxin removal for endotoxin levels <0.1 EU/mg.

· Process Characteristics: Targeted impurity elimination (urea derivatives <0.05%); consistent scale-up performance from 10 kg to 500 kg batches with zero quality fluctuations.

(3) Supply Stability: Combined Self-Owned & Outsourced Capacity, Flexible Fast Delivery, Priority Allocation to Top Clients

· Capacity: Total annual capacity of 400 tons; 70% produced at self-owned Anhui manufacturing base, 30% via qualified outsourced partners with on-site resident technical oversight for full-process quality control.

· Delivery Cycles: Standard grades: 2–3 weeks; ADC specialized grade: 3 weeks; small-batch orders (10–50 kg) delivered within 7 days.

· Inventory: Permanent safety stock ≥30 tons; top clients including WuXi AppTec and Asymchem receive guaranteed production allocation with 100% fulfillment during peak demand.

· Potential Risk Point: 30% outsourced capacity may extend delivery timelines by 3–5 days under extreme environmental production restrictions.

(4) Key Performance Indicators (HF-EDC-ADC ADC Specialized Grade)

· HPLC Purity: ≥99.5%

· Single Impurity: ≤0.08%

· Moisture Content: ≤0.4%

· Heavy Metals: <8 ppm

· Endotoxin Level: <0.1 EU/mg

· Coupling Efficiency: ≥96%

· Inter-Batch Variance: ≤0.3%

(5) Impacts on Downstream Buyers

· ADC/peptide pharmaceutical manufacturers: High crosslinking efficiency minimizes side reactions, boosting drug yields by 5%–8% and cutting impurity levels by 30%; ultra-low endotoxin levels suitable for clinical-grade manufacturing.

· CRO/CDMOs: Optimal cost performance (5%–10% lower pricing than GL Biochem), consistent quality and flexible delivery ideal for medium-small batch fast-iteration projects.

· Risk Mitigation Note: Enhanced batch sampling inspection required for outsourced production batches to avoid sporadic quality fluctuations.

III. Aladdin: Research Reagent Benchmark, Small-Batch High-Purity Precision Process, Ultra-Fast Supply, Specifications Optimized for Advanced Scientific Research

(1) Main Product Models

· E106172: ≥98%, research grade

· A638729: ≥99%, high-purity research grade

· EDC-ULTRA: ≥99.5%, ultra-high purity grade (enzyme-free, apyrogenic)

(2) Production Process: Miniaturized Precision Synthesis + Multi-Stage Recrystallization + Cleanroom Aseptic Packaging for Ultra-Low Impurity & Consistent Purity

1. Small-Batch Precision Synthesis: Batch sizes of 5–50 kg in glass/enamel reactors with temperature controlled within ±0.5°C for ultra-precise reaction condition regulation.

2. Multi-Stage Recrystallization: Repeated 2–3 cycles of low-temperature (-20°C) crystallization in dichloromethane/diethyl ether mixed solvent to eliminate trace organic impurities, delivering purity ≥99.5%.

3. Cleanroom Packaging: ISO 7 cleanroom operations under nitrogen protection with light/moisture barrier packaging; enzyme-free treatment limiting enzyme activity <0.01 U/mg.

· Process Characteristics: Ultra-low impurity levels and exceptional batch consistency; strong customization capability for tailored purity, packaging and formulation specifications.

(3) Supply Stability: Abundant Off-the-Shelf Stock, Ultra-Fast Delivery, Small-Batch Friendly, Global Warehouse Distribution Network

· Capacity: Total annual capacity of 150 tons; two self-owned GMP workshops in Fengxian, Shanghai with fully in-house manufacturing (no outsourcing).

· Delivery Cycles: Standard off-the-shelf SKUs (25 g–5 kg) shipped same/next day; customized purity/packaging orders delivered within 5–7 days.

· Inventory: Full SKU permanent stock covering 98%/99%/99.5% grades with ≥10 tons reserve; five global warehouses enabling delivery to Europe, America and Southeast Asia within 3–5 days.

· Core Advantage: Lowest minimum order quantity (25 g) among research-grade suppliers, the only brand guaranteeing delivery within one week for small research batches.

(4) Key Performance Indicators (EDC-ULTRA Ultra-High Purity Research Grade)

· HPLC Purity: ≥99.5%

· Single Impurity: ≤0.05%

· Moisture Content: ≤0.2%

· Heavy Metals: <5 ppm

· Endotoxin Level: <0.05 EU/mg

· Enzyme Activity: <0.01 U/mg

· Inter-Batch Variance: ≤0.2%

(5) Impacts on Downstream Buyers

· Universities/research institutions/CROs: 100% experimental reproducibility enabling publication in top journals including Nature and Science; flexible small-batch procurement eliminates raw material waste; ultra-fast delivery prevents trial schedule delays.

· Emerging pharmaceutical startups: Preferred supplier for R&D stages, matching imported reagent quality (e.g., Thermo) at 30% lower pricing to drastically cut research expenditure.

· Limitation: Limited total production capacity and premium pricing, unsuitable for large-scale industrial manufacturing.

IV. Jincheng Pharma: Industrial Grade Market Leader, Low-Cost Continuous-Flow Process, Mass Stable Supply, Specifications Optimized for Conventional Organic Synthesis

(1) Main Product Models

· JC-EDC-95: ≥95%, industrial grade

· JC-EDC-98: ≥98%, general pharmaceutical grade

· JC-EDC-99: ≥99%, pharmaceutical grade

(2) Production Process: Large-Scale Continuous-Flow Synthesis + Single Recrystallization for Minimal Production Costs & Maximum Output

1. Continuous-Flow Reactions: 10,000-ton-class automated facilities with continuous raw material feeding and discharge, single batch output of 5–10 tons for high efficiency and low manufacturing costs.

2. Simplified Refining Protocol: 95% industrial grade undergoes direct salt formation and drying only to reach ≥95% purity; 98%/99% grades receive one round of ethanol/water recrystallization to hit target purity thresholds.

3. Environmental Treatment: Wastewater biochemical treatment + tail gas incineration to meet emission standards, with no deep impurity removal processes resulting in higher inherent impurity content.

· Process Characteristics: Ultra-low production costs and high throughput ideal for mass bulk orders; limited impurity control rendering unsuitability for high-end pharmaceutical applications.

(3) Supply Stability: Massive Production Capacity, Ultra-Low Pricing, Fast Delivery, Unlimited Inventory Reserves

· Capacity: Total annual capacity of 300 tons, China’s largest industrial-grade output; self-owned fully automated continuous-flow production base in Zibo, Shandong.

· Delivery Cycles: 95% industrial grade: 1–2 weeks; 98% grade: 2 weeks; bulk orders above 10 tons: 3 weeks.

· Inventory: Permanent stock ≥100 tons with unlimited supply capacity, top choice for mass purchasers in Southeast Asia and the Middle East.

· Core Advantage: Lowest market pricing (50% cheaper than GL Biochem) with zero supply bottlenecks for long-term bulk industrial procurement.

(4) Key Performance Indicators (JC-EDC-98 General Pharmaceutical Grade)

· HPLC Purity: ≥98.0%

· Single Impurity: ≤0.5%

· Moisture Content: ≤1.0%

· Heavy Metals: <50 ppm

· Endotoxin Requirement: No specification threshold

· Inter-Batch Variance: ≤0.8%

(5) Impacts on Downstream Buyers

· Fine chemical/intermediate manufacturers (Southeast Asia/Middle East): Ultimate cost savings for conventional organic synthesis, water treatment and dye manufacturing (non-high-end applications). Stable supply with minimal price volatility ideal for long-term bulk purchasing.

· Key Risk Note: Elevated impurity levels and significant batch fluctuations prohibit use in pharmaceutical, medical aesthetics and diagnostic reagent manufacturing; high moisture absorption requires strict temperature-controlled warehousing.

V. Kaisai Chem: High-Purity Customization Specialist, Medical Aesthetics & Diagnostic-Specific Process, Flexible Supply, Specifications Optimized for Biomaterial Manufacturing

(1) Main Product Models

· KS-EDC-99: ≥99%, high-purity grade

· KS-EDC-99.5: ≥99.5%, high-end customized grade (medical aesthetics & diagnostic reagents)

· KS-EDC-GMP: ≥99%, GMP customized grade

(2) Production Process: Biological-Grade Dedicated Synthesis + Dual Refining + Biocompatibility Treatment for Medical Aesthetics & Diagnostic Applications

1. Biological-Grade Raw Materials: Pharmaceutical-grade propylenediamine/ethylamine feedstock with zero animal-derived components and no pyrogen residues.

2. Mild Reaction Conditions: Controlled low-temperature (5–10°C) weak-base synthesis to minimize side reactions and impurity generation.

3. Dual Refining Protocol: Recrystallization + activated carbon decolorization to eliminate pigment and trace impurities; medical aesthetics grade receives additional biocompatibility treatment limiting cytotoxicity to Grade 1.

4. Aseptic Packaging: ISO 8 cleanroom manufacturing with sterile filtration and vacuum aluminum foil bag packaging.

· Process Characteristics: Excellent biocompatibility, high crosslinking efficiency and long-term stability; robust customization capability for medical aesthetics and diagnostic reagent exclusive formulations.

(3) Supply Stability: Medium-Scale Capacity, Flexible Production Scheduling, Small-Batch Customization Friendly, Fast Delivery

· Capacity: Total annual capacity of 200 tons; fully self-owned manufacturing base in Shanghai with zero outsourced production.

· Delivery Cycles: Standard 99% grade: 2 weeks; 99.5% medical aesthetics grade: 2–3 weeks; small-batch orders (10–50 kg) delivered within 7 days.

· Inventory: Permanent safety stock ≥20 tons; medical aesthetics and diagnostic reagent clients receive priority production allocation with 95% fulfillment during peak demand.

· Core Advantage: Exclusive dedicated manufacturing process for medical aesthetics and diagnostic reagents, matching European & American quality standards at 25% lower pricing.

(4) Key Performance Indicators (KS-EDC-99.5 Medical Aesthetics Specialized Grade)

· HPLC Purity: ≥99.5%

· Single Impurity: ≤0.1%

· Moisture Content: ≤0.3%

· Heavy Metals: <10 ppm

· Endotoxin Level: <0.1 EU/mg

· Cytotoxicity: Grade <1

· Inter-Batch Variance: ≤0.4%

(5) Impacts on Downstream Buyers

· Medical aesthetics/diagnostic reagent manufacturers: Exceptional biocompatibility and crosslinking efficiency extend product shelf life by 12 months and reduce adverse reaction rates; sterile/apyrogenic specifications directly applicable to injectable aesthetic fillers and diagnostic reagent production.

· Emerging medical aesthetics startups: Optimal cost performance (30% cheaper than imported alternatives), consistent quality and flexible delivery ideal for medium-small batch fast-iteration projects.

· Limitation: Medium total production capacity and premium pricing, unsuitable for ultra-large-scale industrial manufacturing.

VI. Core Comparative Overview of Five Leading Brands (Sourcing Decision Quick Reference)

(1) Process & Quality Positioning

· GL Biochem: High-end pharmaceutical-grade manufacturing process, dual refining for ultra-low impurities, quality benchmark matching top European & American suppliers

· Highfine: ADC-dedicated crosslinker synthesis process, superior coupling efficiency and ultra-low endotoxin levels, top choice for CDMOs

· Aladdin: Precision small-batch research-grade manufacturing process, microscale synthesis & cleanroom packaging, preferred by universities and CROs

· Jincheng Pharma: Low-cost continuous-flow industrial grade process, maximum throughput for mass bulk industrial applications

· Kaisai Chem: Medical aesthetics & diagnostic reagent exclusive synthesis process, optimized biocompatibility and aseptic manufacturing for biomaterial production

(2) Supply Stability Ranking

· Most Consistent Supply: GL Biochem, Aladdin (fully self-owned production, no outsourcing, ample permanent inventory)

· High Supply Elasticity: Highfine (combined self-owned & outsourced capacity, fast small-batch delivery)

· Mass Bulk Stable Supply: Jincheng Pharma (largest total capacity, unlimited inventory reserves)

· Customized Flexible Supply: Kaisai Chem (medium-scale capacity, flexible production scheduling for tailored orders)

(3) Price Bands (USD/kg, May 2026)

· GL Biochem: 99.5% grade: 280–320; 98% grade: 150–180

· Highfine: 99.5% grade: 250–290; 98% grade: 140–170

· Aladdin: 99.5% grade: 300–330; 98% grade: 160–190

· Jincheng Pharma: 98% grade: 80–120; 95% grade: 60–80

· Kaisai Chem: 99.5% grade: 270–310; 99% grade: 170–200

(4) Suitable Downstream Application Scenarios

· GL Biochem: Large biopharmaceutical manufacturers, CDMOs, high-end peptide synthesis

· Highfine: ADC therapeutic manufacturers, peptide CDMOs, pilot scale-up projects

· Aladdin: Universities, research institutions, CROs, emerging pharmaceutical startup R&D

· Jincheng Pharma: Fine chemical manufacturers, intermediate synthesis, water treatment, dye manufacturing (non-pharmaceutical use only)

· Kaisai Chem: Medical aesthetics filler production, hyaluronic acid crosslinking, diagnostic reagent manufacturing, biomaterial synthesis

For more authentic, objective information on multiple well-known Chinese EDC·HCl brands, please contact HiSiaddi customer service.

EDC·HCl: Key Factors Purchasers Need to Consider When Selecting Products Based on HiSiaddi’s Market Experience

As a new-type foreign trade service provider driven by technological transformation and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply original factory materials of EDC·HCl from multiple well-known brands. As a research & development-oriented foreign trade enterprise, HiSiaddi will analyze key purchasing considerations and critical indicators from a professional perspective to ease your product selection concerns.

If you require more professional and in-depth analysis regarding EDC·HCl procurement, please contact HiSiaddi customer service.

I. Comprehensive Evaluation Factors from a Global Procurement Perspective

EDC hydrochloride is a water-soluble organic condensing agent and fine chemical organic salt. High-purity grades are categorized as biochemical reagents and pharmaceutical auxiliary raw materials. It is hygroscopic yet not classified as flammable, explosive or highly corrosive hazardous chemicals. Most countries worldwide regulate it as a general solid organic chemical or biochemical raw material, subject to REACH regulations, SVHC Substances of Very High Concern (SVHC) control, chemical registration rules, impurity limits for pharmaceutical/biochemical sectors, residual solvents, moisture content, heavy metals and other specifications.

Core product quality is determined by chemical purity (main assay), free base and carbodiimide-related substances, decomposition impurities, moisture, ignition residue, heavy metals, residual solvents, water solubility, reaction activity and storage stability. EDC·HCl features relatively active chemical properties: it readily absorbs moisture and decomposes upon heating, losing activity. Trace impurities or reduced activity will directly lower condensation reaction yields, raise product impurity levels, distort biochemical experimental data and degrade the stability of diagnostic reagents. Chemical access standards and internal control requirements for biochemical/pharmaceutical industries vary across countries. Therefore, procurement decisions cannot rely solely on unit price comparison; downstream processes, application sectors and target market regulations must be comprehensively integrated for proper product selection.

(I) Compliance Qualification Verification: Align with Global Regulations to Ensure Smooth Customs Clearance, Production and Industry Compliance

Compliance certificates and supporting documents form the foundation for cross-border customs clearance, enterprise internal quality control and downstream product compliance, serving as a priority verification item in early-stage cooperation.

1. Special Certifications and Test Reports Matched to Application Scenarios

· General industrial grade for conventional organic synthesis, coating crosslinking and ordinary chemical additives: REACH registration, SVHC screening reports and basic physical & chemical test data to meet universal global chemical control standards.

· Biochemical reagent grade for university laboratories, routine biochemical experiments and general research synthesis: additional reagent grade certification, water solubility verification, activity validation and standard heavy metal test reports compliant with international biochemical reagent norms.

· Pharmaceutical synthesis grade for pharmaceutical intermediate synthesis, peptide drug condensation and pharmaceutical excipient matching: mandatory supplementary pharmaceutical raw material filings, ICH Q3 series impurity analysis, graded residual solvent testing and hazardous element limit reports to satisfy global pharmaceutical chemical access standards.

· High-end biological/diagnostic grade for in vitro diagnostic reagents, advanced bioconjugation, cell experiments and sterile biochemical systems: extra microbial limit testing, endotoxin screening, particulate matter detection and low-precipitate testing to strictly align with medical and in vitro diagnostic industry standards.

1.

Complete Cross-Border Customs Clearance and Trade Documents This product exists as white crystalline solids and is not classified as hazardous goods, transported per general solid chemical regulations globally. We uniformly provide multi-language Safety Data Sheets (SDS), chemical hazard classification identification reports. Standard customs clearance documents include certificates of origin, batch-by-batch full-item Certificate of Analysis (CoA) and production traceability records. For pharmaceutical and biological diagnostic grade orders, supplementary liquid chromatography purity spectra, residual solvent test reports, heavy metal analysis and activity validation data are supplied to support overseas client internal audits and industry compliance inspections.

2.

3.

Supplier Comprehensive Qualification Screening Prioritize source manufacturers with integrated production capacity covering complete condensation synthesis, salification via acidification, multi-stage recrystallization, deep drying and stabilization treatment. Key audit items include continuous production capacity, batch consistency and third-party authoritative testing qualifications. The core production challenges of this product lie in moisture control, anti-decomposition treatment, suppression of polymeric impurities and sustained reaction activity. Products manufactured with inadequate drying processes or insufficient stabilization treatment are prone to moisture absorption, caking, rapid activity decay and excessive decomposition impurities, which will render downstream reactions ineffective. Before formal cooperation, small sample activity testing, water solubility verification and accelerated stability tests are recommended to confirm process compatibility prior to bulk orders.

4.

(II) Raw Material and Production Process Verification: Lock Synthesis, Purification and Drying Procedures to Guarantee Activity and Purity

Product purity, reaction activity, impurity levels and shelf life are determined by starting material quality, condensation reactions, salification processes, recrystallization purification, vacuum drying and anti-decomposition stabilization treatments — these procedures also form the core criteria for grade classification.

1.

Upstream Raw Material Quality Inspection High-quality products adopt high-purity amines, isocyanate starting materials and high-purity hydrochloric acid, with precise reaction parameter control in closed reaction systems to minimize by-products and polymeric impurities. Subsequent multi-stage recrystallization for purification, dedicated free base removal, graded low-temperature vacuum drying and inert gas displacement stabilization strictly control moisture and residual solvents. Finished products feature high purity, excellent water solubility, minimal decomposition impurities and slow activity attenuation during long-term storage, delivering strong compatibility with peptide synthesis, biochemical reactions and crosslinking systems. Low-end products utilize industrial-grade raw materials with simplified recrystallization and deep drying workflows, typically suffering from excessive moisture, severe moisture-induced caking, rapid activity loss and abundant polymeric impurities, rendering them unsuitable for pharmaceutical synthesis, high-end biochemistry and diagnostic applications. When purchasing pharmaceutical or biological grades, suppliers may be requested to provide quality inspection certificates for starting materials and reaction reagents.

2.

3.

Core Production Process Classification and Confirmation Standard complete production workflow: High-purity raw material blending → condensation reaction to produce crude carbodiimide → salification with hydrochloric acid → crude product filtration and residue removal → multi-stage recrystallization to eliminate free base and polymeric impurities → residual solvent stripping → graded low-temperature vacuum drying → inert gas displacement stabilization → sieving → hermetic packaging → constant-temperature warehousing.

4.

· General industrial grade: Basic synthesis + two-stage recrystallization, cost-effective for ordinary chemical engineering, crosslinking and conventional organic synthesis.

· Biochemical reagent grade: Multi-stage recrystallization + deep drying with strict moisture and standard impurity control, suitable for laboratory research and general biochemical reactions.

· Pharmaceutical synthesis grade: High-purity refining + specialized impurity removal + low residual solvent treatment aligned with pharmaceutical chemical internal control standards, applied in drug and peptide condensation procedures.

· High-end biological/diagnostic grade: Extreme moisture control + low endotoxin + aseptic processing + long-term stabilization, exclusively for in vitro diagnostic reagents, bioconjugation and high-cleanliness biochemical systems. Formal production lines implement grade-separated manufacturing; high-end pharmaceutical and biological grades are produced in independent clean workshops with dedicated drying equipment to avoid cross-contamination, prohibiting low-grade products from being falsely labeled as high-purity grades.

1. Quality Control and Batch Consistency Evaluation Mass continuous production is available for all grades with regular stock in place; customized special specifications are produced against orders. Request multi-batch CoA documents, liquid chromatography purity spectra, moisture, activity and residual solvent test data, with focus on monitoring batch fluctuations in main assay, decomposition impurities, free base, moisture, water solubility and reaction activity. Long-term partnerships can lock production processes and testing methods to ensure consistent downstream reaction performance across batches. Suppliers shall also provide stability data under normal moisture-proof storage and accelerated stability testing to adapt to warehousing and ocean shipping environments with varying temperature and humidity worldwide. Manufacturers with independent drying and stabilization capabilities are preferred; suppliers only outsourcing crude products for repackaging present high risks of unstable moisture and activity indicators.

(III) Grade and Specification Selection: Match Application Scenarios and Processes to Avoid Parameter Mismatch Risks

EDC hydrochloride available on the market is categorized by purity grade, moisture control standards, impurity limits and biological indicators. Improper selection will reduce reaction yields, skew experimental data and render end products unqualified, requiring precise matching with application fields, reaction systems and equipment operating conditions.

1. Grade Classification by Application Scenario

· General industrial grade: Ordinary organic synthesis, polymer crosslinking, industrial additives and conventional chemical reactions.

· Biochemical reagent grade: University/research institute laboratories, routine biochemical experiments and basic synthetic R&D.

· Pharmaceutical synthesis grade: Pharmaceutical intermediates, peptide drugs and pharmaceutical raw material condensation reactions.

· High-end biological/diagnostic grade: In vitro diagnostic reagents, bioconjugation, cell experiments and high-cleanliness biochemical systems. Grades cannot be cross-substituted across application fields.

1.

Physical Form and Process Compatibility The mainstream product form is free-flowing crystalline powder; granular products are available upon customer demand. Fine powder dissolves rapidly, suitable for batch reactors and laboratory small-scale trial systems; granular material delivers superior fluidity, low dust generation and slower moisture absorption, ideal for automated continuous feeding and closed mass production equipment. Water solubility and solution clarity must be verified: turbid solutions or excessive insoluble matter will interfere with reactions and experimental results.

2.

3.

Core Index Agreements in Contracts Procurement contracts shall clearly specify main assay (chemical purity), related substances (decomposers/polymers/free base), moisture, ignition residue, heavy metals, residual solvents, solution clarity and allowable tolerances. Pharmaceutical grades impose stricter limits on residual solvents and hazardous elements; biological/diagnostic grades add contractual clauses for microbial limits and bacterial endotoxins. All indicators shall align with industry standards for target sectors as the basis for goods acceptance and dispute resolution upon delivery.

4.

5.

Packaging and Minimum Order Rules Given strong hygroscopicity, standard packaging consists of inner moisture-proof PE bags + aluminum foil vacuum sealing, with outer fiber drums or plastic drums. Pharmaceutical and biological diagnostic grades adopt clean moisture-proof packaging; high-end varieties include desiccants and nitrogen filling to prevent moisture absorption and decomposition. Industry standard measurement units are kilograms and metric tons; small reagent packaging can be customized on demand. Small sample testing is mandatory prior to bulk orders, including dissolution tests, condensation reaction activity verification and short-term moisture-proof stability observation.

6.

(IV) Commercial Terms and Comprehensive Cost Accounting: Calculate Full-Lifecycle Usage Cost Based on Fine Chemical Properties

As a bulk fine chemical/biochemical raw material, EDC·HCl procurement cost cannot be measured solely by unit price. Comprehensive usage cost shall be calculated incorporating purity, moisture retention, activity stability, impurity content, single-batch feeding dosage and downstream product yield. Low-priced products with high moisture and poor activity incur large feeding losses and excessive by-products, leading to higher overall operational costs.

1. International Trade Quotation Modes

· FOB China Port: Quotation covers goods, standard moisture-proof packaging, domestic warehousing, chemical inspection and export declaration fees. International freight, insurance, destination port customs clearance and local chemical registration are borne by buyers, suited for large chemical enterprises, pharmaceutical groups and scaled biochemical manufacturers with long-term bulk procurement for optimal comprehensive cost.

· CIF Destination Port: Covers full ocean freight, cargo insurance, port charges, documents and special chemical handling fees coordinated uniformly by suppliers, featuring simple operation for overseas small factories, laboratories, trading companies and end-users with small-batch procurement. Tiered volume pricing and annual long-term contract pricing are available for stable pricing in long-term cooperation.

1.

Payment Terms, Lead Time and Dispute Definition Major international trade settlement methods include T/T and irrevocable letters of credit. Standard grades are in stock with short lead times; customized ultra-low moisture, low-endotoxin and sterile batches require extended production cycles due to additional refining and processing procedures. Contracts shall define dispute judgment criteria: substandard main assay, excessive impurities/free base, over-limit moisture, turbid dissolution, significant activity decline and mismatched goods. Agreements shall specify internationally recognized third-party testing institutions, re-inspection procedures and return & replacement rules. Clauses shall also state that minor caking under normal sealed moisture-proof storage will not impair activity or performance after crushing, clarifying liability allocation between both parties.

2.

3.

Warehousing Requirements and Minimum Order Management Universal storage requirements for all grades: Cool, dry, ventilated, room-temperature sealed moisture-proof storage, kept away from humid environments, heat sources, acids, alkalis and strong oxidants. Pharmaceutical and biological diagnostic grades require dedicated constant-temperature low-humidity warehouses with strict environmental humidity control. Large-volume goods shall avoid repeated repackaging of original containers to prevent moisture-induced deterioration. Both parties shall agree on free domestic warehousing cycles; goods are prohibited from long-term open-air or high-humidity port storage.

4.

(V) Packaging, Storage, Transportation and Logistics Control: Comply with Standards for Hygroscopic Solid Chemicals – Moisture Barrier, Sealing, Temperature Control and Anti-Extrusion

Core risks during storage and transportation of this product: moisture absorption and caking, thermal decomposition, activity attenuation and foreign impurity contamination. All operations shall follow international logistics specifications for hygroscopic fine chemicals with core control principles: vacuum sealing, built-in moisture protection, cool room-temperature transit and anti-extrusion packaging.

1. Packaging Standards

· General industrial/reagent grade: Thickened inner moisture-proof PE bags, middle aluminum foil vacuum sealing, outer reinforced chemical fiber drums printed with product name, grade, batch number, moisture-proof storage instructions and shelf life.

· Pharmaceutical/biological diagnostic grade: Clean non-precipitation packaging with food-grade desiccants inside; high-end batches filled with nitrogen to fully isolate water vapor. All packaging undergoes factory testing for tightness, drop resistance and leakage prevention before shipment.

1.

Transportation Control Ocean and land chemical transportation are permitted without dedicated hazardous goods vehicles or holds. Dry and ventilated logistics channels are prioritized to avoid long-term transit in rainy or high-humidity regions. Air shipments are declared as general solid chemicals. Logistics partners with dry warehousing conditions are preferred; cargo insurance can be purchased for full batches with real-time logistics tracking. Transit warehouses must remain dry and ventilated with zone-separated storage, prohibited from co-storage with water-containing materials, acids, alkalis and corrosive goods.

2.

3.

On-Site Usage Specifications Upon cargo arrival at the port, transfer goods to dry warehouses immediately and inspect packaging integrity. Sampling and feeding operations shall be conducted in low-humidity ventilated environments with shortened open-container exposure time to minimize moisture absorption. After partial extraction, reseal containers promptly and replenish moisture-proof protection. Separate storage for different grades and batches; establish inbound/outbound ledgers and implement first-in-first-out inventory management to ensure product use within shelf life.

4.

(VI) Technical Support and After-Sales Service: Focus on Reaction Application and Stability to Resolve Activity, Dissolution and Impurity Issues

Moisture content, activity and impurities of EDC·HCl directly affect condensation reactions and biochemical experimental results, making targeted application guidance and troubleshooting across different systems essential.

1.

Application Process Technical Support We provide samples, complete technical manuals, application case studies and activity data, recommending optimal feeding ratios, storage and operation standards aligned with client reaction systems (NHS/HOBt mixing ratios, reaction temperature, pH value) and production equipment. Optimization solutions are offered for common issues including moisture-induced caking, turbid dissolution, low reaction activity, excessive by-products and rapid storage activity loss. We also interpret REACH regulations, chemical registration requirements and pharmaceutical/biochemical raw material access rules for target countries.

2.

3.

Post-Delivery Re-Inspection Coordination Sampling complies with international fine chemical sampling standards. Clients may self-inspect basic indicators including appearance, moisture and solution clarity, or entrust third-party laboratories to re-test core metrics such as main assay, related substances, free base, residual solvents, heavy metals and activity. Full traceability, compensation and return procedures apply for test results failing contractual specifications.

4.

5.

Compliance Document Assistance Multi-language SDS, full CoA documents, testing spectra, qualification certificates and traceability records are provided on demand to assist clients with local chemical registration and internal enterprise compliance audits. We synchronize updates on global fine chemical and biochemical reagent regulatory changes.

6.

II. Core Control Indicators by Application Sector

Five major mainstream global application segments are defined below, with clear control priorities for general industrial synthesis & chemical additives, research laboratories & general biochemical experiments, pharmaceutical & peptide synthesis, in vitro diagnostics & high-end biological fields, and international chemical/biochemical raw material distributors.

(I) General Industrial Synthesis & Chemical Additive Purchasers

Core priorities: Stable main assay, controllable moisture, good fluidity, cost-effectiveness and storage resistance

1. Consistent main assay across batches to meet basic industrial reaction requirements

2. Controlled moisture limits to prevent extensive caking interfering with feeding

3. Clear dissolution without obvious insoluble matter compatible with conventional reaction systems

4. Ignition residue and standard impurities compliant with industrial chemical norms

5. Storage stability with no rapid activity decay under normal moisture-proof room-temperature storage

6. Good powder fluidity matching standard feeding equipment

(II) Research Laboratories & General Biochemical Experiment Purchasers

Core priorities: Qualified purity, low impurities, complete dissolution, stable activity and reproducible experimental results

1. Chemical purity meeting reagent grade standards with minimal batch variation

2. Low free base and decomposition impurities to reduce experimental interference

3. Low moisture to avoid extraneous impurities introduced into experimental systems

4. Transparent and homogeneous dissolved solution ensuring experimental accuracy

5. Stable reaction activity for consistent parallel experimental data

6. Short-term stability without deterioration or activity loss under routine laboratory storage

(III) Pharmaceutical & Peptide Synthesis Purchasers

Core priorities: High purity, low related substances, compliant residual solvents, qualified heavy metals and stable activity

1. Main assay meeting stringent pharmaceutical grade standards with minimal batch deviation

2. Strictly limited related substances (decomposers, polymers, free base) as core control indicators to avoid impurity introduction into pharmaceutical products

3. Residual solvents fully compliant with ICH Q3C classification and limit specifications

4. Heavy metals and hazardous elements complying with universal pharmaceutical raw material thresholds

5. Rigorous moisture control to prevent excessive water content in pharmaceutical synthesis systems

6. Sustained long-term activity to maintain stable condensation efficiency during mass production cycles

(IV) In Vitro Diagnostic & High-End Biological Sector Purchasers

Core priorities: Ultra-low moisture, low endotoxin, microbial compliance, low precipitation and long-lasting stable activity

1. Extreme moisture control to fundamentally eliminate moisture absorption and system interference

2. Bacterial endotoxin and microbial limits as core control items meeting biosafety requirements for diagnostic systems

3. Chemical purity and organic impurities controlled under internal standards stricter than pharmaceutical grades

4. Undetectable insoluble particles and clear dissolution to guarantee precision of diagnostic reagents

5. Low precipitation with no abnormal leaching from packaging or products contaminating end systems

6. Long-term stability with no obvious fluctuations in activity or indicators over extended storage

(V) International Chemical/Biochemical Raw Material Distributor Purchasers

Core priorities: Strong storage & transportation moisture resistance, intact packaging, complete supporting documents, full batch traceability and broad compatibility

1. Transportation & storage stability without moisture absorption, caking or activity degradation after ocean shipping and multi-country transit

2. Intact vacuum moisture-proof packaging free from damage, powder leakage or water intrusion

3. Consistent quality across batches of the same grade to suit diverse downstream end-users

4. Basic physical and chemical indicators compliant with corresponding grade standards with clear batch traceability

5. Complete supporting documents including SDS, CoA, qualification certificates and test reports to satisfy cross-border customs clearance and client audits

For more professional and in-depth analysis on EDC·HCl procurement, please contact HiSiaddi customer service.